POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
November 14, 2022 07:15 ET
|
POINT Biopharma
INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022 07:00 ET
|
POINT Biopharma
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
October 27, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has...
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
October 26, 2022 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
Outlook on the Radiotheranostics Global Market to 2027 - Regulatory Approval of Numerous Radiotheranostics Pairs is Expected to Boost Their Adoption for Cancer Treatments
October 25, 2022 08:18 ET
|
Research and Markets
Dublin, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The "Global Radiotheranostics Market by Radioisotope, Application, End-user and Region: Competition Forecast and Opportunities to 2027" report has been...
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
October 17, 2022 08:30 ET
|
POINT Biopharma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
October 13, 2022 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production...
Outlook on the Nuclear Medicine Equipment Global Market to 2030 - Rising Adoption of Nuclear Medicine Equipment and Emergence of Innovative & Advanced Equipment is Driving Growth
October 07, 2022 07:53 ET
|
Research and Markets
Dublin, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Equipment Market By Product, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has...
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
September 16, 2022 16:30 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET
|
POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...